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M A J O R A R T I C L E
Exposure to Holoendemic Malaria Results
in Suppression of Epstein-Barr Virus–Specific T
Cell Immunosurveillance in Kenyan Children
Ann M. Moormann,1 Kiprotich Chelimo,4 Peter O. Sumba,4 Daniel J. Tisch,2 Rosemary Rochford,3
and James W. Kazura1
1Center for Global Health and Diseases and 2Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio;
3Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse; 4Kenya Medical Research
Institute, Center for Vector Biology and Control Research, Kisumu, Kenya
Background. Malaria and Epstein-Barr virus (EBV) infection are cofactors in the pathogenesis of endemic
Burkitt lymphoma (eBL). The mechanisms by which these pathogens predispose to eBL are not known.
Methods. Healthy Kenyan children with divergent malaria exposure were measured for responses to EBV latent
and lytic antigens by interferon (IFN)–g enzyme-linked immunospot (ELISPOT) assay and interleukin (IL)–10
ELISA. Phytohemagglutinin (PHA), purified protein derivative (PPD), and T cell epitope peptides derived from
merozoite surface protein (MSP)–1, a malaria blood-stage antigen, were also evaluated.
Results. Children 5–9 years old living in an area holoendemic for malaria had significantly fewer EBV-specific
IFN-g responses than did children of the same age living in an area with unstable malaria transmission. This effect
was not observed for children !5 years old or those 19 years old. In contrast, IFN-g responses to PHA, PPD, and
Plasmodium falciparum MSP-1 peptides did not significantly differ by age. IL-10 responses to EBV lytic antigens,
PPD, and PHA correlated inversely with malaria exposure regardless of age.
Conclusions. Children living in malaria-holoendemic areas have diminished EBV-specific T cell immuno-
surveillance between the ages of 5 and 9 years, which coincides with the peak age incidence of eBL.
Burkitt lymphoma was first described in African chil-
dren in 1958 [1]. The highest incidence of endemic
Burkitt lymphoma (eBL) is in equatorial Africa and
Papua New Guinea (5–15 cases/100,000 children) [2,
3]. Within Africa, there is an uneven geographic dis-
tribution of eBL, which led Dalldorf [4] in 1962 to
suggest that malaria may be a risk factor for lympho-
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magenesis. In fact, there is a strong correlation between
residence in areas of intense, perennial malaria trans-
mission (i.e., holoendemic malaria) and the incidence
of eBL [3, 5].
eBL, the first human cancer discovered to have a viral
etiology, is associated with Epstein-Barr virus (EBV)
infection [6]. EBV is restricted to humans and infects
the vast majority of the world’s population [7]. In coun-
tries such as Kenya, EBV infection generally occurs by
2 years of age [8–11] and persists for life as a latent
infection in memory B cells [12]. The lytic phase of
viral replication is thought to occur after plasma cell
differentiation [13–15]. The virus is periodically shed
in the saliva, suggesting that there is ongoing lytic-cycle
reactivation [16].
Immunosurveillance and control of EBV is domi-
nated by CD8+ human leukocyte antigen (HLA) class
I–restricted cytotoxic T lymphocyte (CTL) interferon
(IFN)–g responses to both latent and lytic viral epitopes
[17, 18]. An EBV-specific CD8+ T cell subset that has
reduced cytotoxicity and that secretes interleukin (IL)–
10 has also been described [19]. Two possible but not
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Table 1. Study participant demographics.
Site, characteristic
Age group
All1–4 years 5–9 years 10–14 years
Kisumu
Study participants enrolled, no. 32 36 36 104
Hemoglobin level, mean, g/dL 9.7 12.2 12.5 11.6
Children with malaria-positive smear,a % 77 72 83 77
Body temperature, mean, C 36.9 36.7 37.0 36.9
Nandi
Study participants enrolled, no. 36 48 43 127
Hemoglobin level, mean, g/dL 12.0 12.9 13.5 12.8
Children with malaria-positive smear,a % 8 14 26 16
Body temperature, mean, C 37.2 37.3 37.0 37.2
a Plasmodium falciparum prevalence differed significantly between study sites ( ).P ! .0001
mutually exclusive models have been proposed to explain how
holoendemic malaria could affect EBV latency and immunity
in children and thereby increase the risk of eBL: suppression
of EBV-specific T cell immunity and/or expansion of the la-
tently infected B cell pool (reviewed in [20, 21]). The few studies
that have investigated the role played by malaria in T cell con-
trol of EBV-infected B cells in clinical samples have used an in
vitro regression assay that measures the ability of T cells to
control the outgrowth of EBV-transformed B lymphocytes [22–
24]; regression of colonies is thought to be mediated by T cells
that express CD8 and produce IFN-g [25, 26]. Using this assay,
Moss et al. [23] found that adults living in malaria-holoendemic
regions of Papua New Guinea had impaired EBV-specific T cell
responses. Later observations from The Gambia reported that
children experiencing acute clinical malaria had impaired EBV-
specific T cell immunity [22, 24]. However, conclusions from
this earlier work were based on a relatively small number of
children or on adults with mature T cell immunity, whose
responses might differ from those of children. In addition,
regression assays do not identify the effector T cells or cytokine
mediators involved in the control of EBV-infected B cells, and
no distinction was made between EBV-specific immunosup-
pression and generalized depression of T cell immunity.
The study described here investigated the effect of malaria
on EBV immunity and assessed whether the intensity and du-
ration of malaria exposure influences EBV-specific IFN-g and
IL-10 responses in healthy children from 2 epidemiologically
distinct areas of western Kenya that differ markedly in the
incidence of eBL [3, 5, 27, 28]. In addition, malaria-specific
cytokine responses were examined concomitantly to address
the question of whether there are global versus EBV-specific
alterations in T cell immunity in children exposed to malaria.
PARTICIPANTS, MATERIALS, AND METHODS
Participants. Approval for this study was obtained from the
Kenya Medical Research Institute (KEMRI) National Ethical
Review Committee and the Institutional Review Board for Hu-
man Studies at the University Hospitals of Cleveland, Case
Western Reserve University. Written, informed consent was ob-
tained from the guardians or parents of the study participants.
Study participant recruitment and sample collection were
conducted in July–August 2002 in 2 epidemiologically distinct
areas of Kenya (Kisumu District and Nandi District), as de-
scribed elsewhere [11]. The characteristics of the study popu-
lation are summarized in table 1. Children from the holoen-
demic-malaria transmission area are referred to as “Kisumu
children” ( ), and children from the sporadic, unstablenp 104
malaria transmission area are referred to as “Nandi children”
( ). Children (1–14 years old) were enrolled if they hadnp 127
overall good health and were excluded from analysis if they
were EBV seronegative [11]. Of note, 77% of the Kisumu chil-
dren had asymptomatic Plasmodium falciparum infection de-
tected by blood smear, which is typical for resident children
from this area. In contrast, 16% of the Nandi children had
positive blood smears after a recent malaria epidemic, dem-
onstrating the dramatic difference in malaria exposure between
the 2 populations.
Sample collection. Peripheral blood was collected in so-
dium-heparinized tubes and transported to the Case Western
Reserve University laboratory located at KEMRI’s Center for
Vector Biology and Control Research in Kisumu for processing
the same day. Peripheral blood mononuclear cells (PBMCs)
were separated from whole blood by ficoll-hypaque density
gradient centrifugation and suspended in RPMI 1640 (GIBCO)
supplemented with 10% heat-inactivated human AB serum, 50
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Table 2. Epstein-Barr virus (EBV) lytic and latent peptides.
EBV
protein Cycle
Peptide
pool
Amino acid
HLA
restrictionSequence Residues
BRLF1 Lytic EP1 DYC NVL NKE F EBV 28–37 A24
BRLF1 Lytic EP1 RVR AYT YSK EBV 148–156 A3
BZLF1 Lytic EP1 RAK FKQ LL EBV 190–197 B8
BMLF1 Lytic EP1 GLC TLV AML EBV 280–288 A2
EBNA3A Latent EP2 FLR GRA YGL EBV 325–333 B8
EBNA3A Latent EP2 RPP IFI RRL EBV 379–387 B7
EBNA3A Latent EP2 SVR DRL ARL EBV 596–604 A2
EBNA3A Latent EP2 RLR AEA QVK EBV 603–611 A3
EBNA3B Latent EP2 TYS AGI VQI EBV 217–225 A24
EBNA3B Latent EP2 VEI TPY KPT W EBV 657–666 B44
EBNA3C Latent EP2 RRI YDL IEL EBV 258–266 B27
NOTE. EBNA, Epstein-Barr nuclear antigen; HLA, human leukocyte antigen.
mg/mL gentamicin, 10 mmol/L HEPES, and 2 mmol/L gluta-
mine for the cytokine-stimulation assays.
Peptide selection. Molecular HLA class I genotyping was
performed previously on a random, unrelated subset of resi-
dents from each study population [29]. The frequency of HLA
class I alleles was similarly heterogeneous in Kisumu and Nandi
but not significantly different from each other. Therefore, our
selection of HLA class I–restricted epitope peptides did not
create a response bias between study populations that would
result from differences in HLA genotype [29]. Previously de-
scribed HLA class I–restricted EBV epitope peptides from im-
munodominant lytic and latent antigens [17, 18] were selected
and pooled. Peptides from EBV lytic (BRLF1, BZLF1, and
BMLF1) and EBV latent (Epstein-Barr nuclear antigen [EBNA]
3A, EBNA3B, and EBNA3C) antigens were selected on the basis
of their predicted binding affinities to prevalent HLA alleles in
our study population (table 2). Peptides were synthesized and
purified to 195% by high-performance liquid chromatography
and were lyophilized for stability (Sigma Genosys). Peptides
were reconstituted in 30% (wt/vol) dimethyl sulfoxide and di-
luted in sterile PBS (GIBCO) to a concentration of 0.1 mg/mL.
EBV peptides were pooled so that each peptide was used at a
final concentration of 10 mg/mL.
Malaria-specific cytokine responses were assessed using pre-
viously described T cell epitopes of merozoite surface protein
(MSP)–1, a protein expressed during the erythrocytic stage of
the parasite life cycle. A C-terminal peptide referred to as M1
(VTHESYQELVKKLEALEDAV; residues 20–39) [30] and an N-
terminal peptide referred to as M2 (GISYYEKVLAKYKDDLE;
residues 1467–1483) [31] were used for ex vivo cytokine-stim-
ulation assays. The specificity of malaria-peptide responses was
tested on PBMCs from 20 malaria-unexposed adult US vol-
unteers. EBV-seropositive US PBMC donors had robust cyto-
kine responses to the EBV peptides but lacked responses to the
malaria peptides (data not shown). Two positive controls were
used to stimulate PBMCs/well: the mitogen phytohe-51 10
magglutinin (PHA; Sigma-Aldrich) at 1 mg/mL and purified
protein derivative (PPD) at 10 mg/mL (Tubersol 5 TU, Ameri-
source Bergen). PBS was added to PBMCs/well as the60.5 10
negative control and represented the background level of IFN-
g produced by unstimulated cells.
Cytokine assays. IFN-g enzyme-linked immunospot (ELI-
SPOT) assays were performed using sterile Millipore MAIP
ELISPOT 96-well microtiter plates precoated at 4C overnight
with 5 mg/mL human anti–IFN-g monoclonal antibody (En-
dogen M-700A). The plates were washed with sterile PBS and
blocked with 10% heat-inactivated fetal bovine serum. PBMCs
plated at cells/well plus stimulant were incubated at60.5 10
37C in 5% CO2 for 72 h. Plates were washed and a second
biotinylated anti–IFN-g monoclonal antibody (Endogen M-
701B) was applied (0.75 mg/mL) for 1.5 h at 37C, followed by
washing, incubation with a 1:2000 dilution of streptavidin-
conjugated horseradish peroxidase (DAKO P0397) for 2 h at
room temperature, washing, and color development by addi-
tion of 1% 3-amino-9-ethyl-carbazole in 0.1 mol/L acetate
buffer catalyzed by 0.015% hydrogen peroxide. The reaction
was stopped after 10–20 min by washing with distilled water.
Plates were dried in the dark at room temperature. The number
of spot-forming units per well was counted using ImmunoSpot
scanning and imaging software (version 4; Pharmingen). Re-
sults are expressed as spot-forming units per PBMCs.61 10
IL-10 ELISAs were performed after PBMC stimulation under
conditions similar to those of the IFN-g ELISPOT assay but
with a final concentration of cells/well in 200 mL of60.2 10
complete RPMI in U-bottom microtiter plates (Microtest; BD).
Cell culture supernatants were removed after 72 h and tested
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Table 3. Aggregate cytokine responses, by children (1–14
years old) with divergent malaria exposure.
Assay, stimulant
Proportion (%) positive
PKisumu Nandi
IFN-g ELISPOT assay
EP1 36/104 (34.6) 52/117 (44.4) .14
EP2 30/104 (28.8) 41/117 (35.0) .32
M1 17/103 (16.5) 26/113 (23.0) .23
M2 25/104 (24.0) 31/113 (27.4) .57
PPD 90/103 (87.4) 103/115 (89.6) .61
PHA 92/104 (88.5) 109/117 (93.2) .22
IL-10 ELISA
EP1 2/104 (1.9) 22/126 (17.5) .0001
EP2 1/104 (1.0) 6/126 (4.8) .095
M1 5/104 (4.8) 14/126 (11.1) .084
M2 7/104 (6.7) 18/126 (14.3) .067
PPD 30/102 (29.4) 76/123 (61.8) .00001
PHA 68/104 (65.4) 103/127 (81.1) .0067
NOTE. Not all children had a sufficient peripheral blood mononuclear cell
yield to test every stimulation condition, as reflected by the denominators.
Boldface type indicates a significant difference ( ) between Kisumu andP ! .05
Nandi children for that stimulant. ELISPOT, enzyme-linked immunospot;EP1,
Epstein-Barr virus (EBV) lytic peptide pool; EP2, EBV latent peptide pool; M1
and M2, malaria peptides; PHA, phytohemagglutinin; PPD, purified protein
derivative.
Figure 1. Proportion of interferon (IFN)–g enzyme-linked immunospot
(ELISPOT) responders, by age group. The proportion of IFN-g ELISPOT
responders was compared between study sites according to the following
age groups: 1–4-year-olds (A), 5–9-year-olds (B), and 10–14-year-olds
(C). Black bars show positive responders from Kisumu, and white bars
show positive responders from Nandi. Stimulation conditions included
the following: an Epstein-Barr virus (EBV) lytic peptide pool (EP1); an EBV
latent peptide pool (EP2); malaria peptides (M1 and M2); purified protein
derivative (PPD); and phytohemagglutinin (PHA). Asterisks indicate that
significantly fewer 5–9-year-olds from Kisumu responded to the EBV lytic
( ) and EBV latent ( ) peptide pools than did Nandi childrenPp .003 Pp .03
of the same age (x2 Fisher’s exact test).
for IL-10 by ELISA as described elsewhere [27]. Values for
baseline (unstimulated) culture supernatants were subtracted
from those for the peptide/mitogen-stimulated culture super-
natants. The concentration of cytokine secreted was determined
against a standard curve by use of recombinant IL-10 with a
sensitivity of 10 pg/mL.
Data analyses. Analyses were conducted using SAS (ver-
sion 8.2; SAS Institute). An IFN-g ELISPOT response was con-
sidered to be positive if the proportion of spot-forming units
in the stimulated well was significantly greater than that in the
unstimulated background well by a x2 Fisher’s exact test (P !
). Proportions of responders were compared across study.05
sites and age categories by use of a x2 Fisher’s exact test. An
IL-10 ELISA response to the malaria peptides was considered
to be positive if it was 12 SDs above the mean response for
the malaria-naive negative controls; the cutoff value for MSP-
1 M1 and M2 peptides was 40 pg/mL. Responses to EBV pep-
tides were found only for PBMCs from EBV-seropositive do-
nors (data not shown). A x2 test for homogeneity was used to
determine whether the proportion of children with IFN-g and
IL-10 responses was significantly different from that of the
adults. Continuous values of IFN-g precursor frequency or IL-
10 ELISA values among positive responders were compared
across study sites by use of a 2-sided Wilcoxon (Mann-Whitney
U) rank sum test. The correlation between an individual’s re-
sponse to both cytokines was assessed by use of the McNemar
test.
RESULTS
IFN-g responses in children with differing exposure to malaria.
Aggregate IFN-g ELISPOT responses in 1–14-year-old children
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Figure 2. Magnitude of interferon (IFN)–g enzyme-linked immunospot (ELISPOT) responses, by each age group. The magnitude of Epstein-Barr virus
(EBV) lytic (A) and latent (B) IFN-g responses was compared by age group and by residence (Kisumu vs. Nandi) for positive responders only. IFN-g
responses are expressed as spot-forming units per peripheral blood mononuclear cells (PBMCs). The no. of spot-forming units for each61 10
responder is represented as black circles for Kisumu children and as white squares for Nandi children, and a median bar is shown for each age
group.
from the malaria-holoendemic area in Kisumu District and the
malaria epidemic–prone area in Nandi District are shown in
table 3. No significant differences in IFN-g ELISPOT responses
to the EBV lytic peptide pool (EP1: BRLF1, BZLF1, and
BMLF1), the EBV latent peptide pool (EP2: EBNA3A, EBNA3B,
and EBNA3C), MSP-1 T cell epitopes (M1 and M2), PPD, or
PHA were observed when children of all ages with different
cumulative malaria exposure were compared.
Because malarial infection and clinical morbidity are highest
in children !5 years old and because protection against malaria
is acquired with age and duration of exposure to malaria [32,
33], we categorized the study participants into age groups as
follows: (1) 1–4 years old, when malaria susceptibility is the
greatest and the peak incidence of eBL has not yet been reached;
(2) 5–9 years old, when malaria susceptibility is declining and
the incidence of eBL is greatest; and (3) 10–14 years old, when
antimalaria immunity has developed and the incidence of eBL
has declined. IFN-g ELISPOT responses were analyzed accord-
ing to age group and compared between the malaria-endemic
study sites. Although the proportion of EBV-specific responders
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Figure 3. Proportion of interleukin (IL)–10 enzyme-linked immunospot
(ELISPOT) responders, by age group. The proportion of IL-10 ELISA re-
sponders was compared between study sites according to the following
age groups: 1–4-year-olds (A), 5–9-year-olds (B), and 10–14-year-olds
(C). Black bars show positive responders from Kisumu, and white bars
show positive responders from Nandi. Stimulation conditions included
the following: an Epstein-Barr virus (EBV) lytic peptide pool (EP1); an EBV
latent peptide pool (EP2); malaria peptides (M1 and M2); purified protein
derivative (PPD); and phytohemagglutinin (PHA). Asterisks indicate that
significant differences between Kisumu and Nandi children were observed
among 5–9-year-olds for EP1 ( ) and PPD ( ) and amongPp .009 P ! .001
1–4-year-olds for PPD and PHA ( , for both). Among children 10–P ! .001
14 years old, the P value for the difference between Kisumu and Nandi
children for EP1 was .051.
was similar for Kisumu and Nandi children aged 1–4 and 10–
14 years (figure 1A and 1C), fewer 5–9-year-old children from
Kisumu than from Nandi produced IFN-g to both the EBV
lytic (EP1, 21.6% vs. 53.1%; ) and the EBV latent (EP2,Pp .003
18.9% vs. 40.8%; ) peptides (figure 1B). In contrast,Pp .03
the proportion of IFN-g responders to the MSP-1 peptides,
PHA, and PPD did not significantly differ by age group or
malaria exposure. Interestingly, when the proportion of EBV
responders was compared between age groups among the Ki-
sumu children, the lowest proportion was found in the 5–9-
year-olds (18.9%) compared with the 1–4-year-olds (43.8%)
and the 10–14-year-olds (25.7%) ( ). This age-associatedP ! .001
loss of EBV-specific IFN-g response was not observed for the
Nandi children.
We next compared the magnitude of IFN-g responses among
the Kisumu and Nandi children with positive ELISPOT re-
sponses. The range of positive IFN-g responses was highly
variable: 12–836 sfu/ PBMCs for EP1 and 16–132261 10
sfu/ PBMCs for EP2. Median responses were not sig-61 10
nificantly different between age groups and study sites for either
of the EBV peptide pools (figure 2).
IL-10 responses by children with differing exposure to
malaria. Aggregate IL-10 ELISA responses in 1–14-year-old
children from the malaria-holoendemic area in Kisumu and
malaria epidemic–prone area in Nandi are shown in table 3.
We observed significantly fewer IL-10 responders to the EBV
lytic peptide pool ( ), PPD ( ), and PHAPp .0001 Pp .00001
( ) in children from Kisumu than from Nandi. InPp .0067
contrast, the proportion of IL-10 responders to the EBV latent
peptide pool and the malaria peptides was similar between
study sites.
Children were grouped by age as described above, and the
proportion of IL-10 responders to each stimulus was then com-
pared by study site (figure 3). Analysis of age-specific IL-10
responses to the EBV lytic peptides (EP1) demonstrated that
5–9-year-old Kisumu children had significantly fewer responses
( ) than did Nandi children of the same age. TherePp .009
were also fewer EP1 responders in the 10–14-year-old group
of Kisumu children compared with Nandi children of the same
age ( ). There were not enough children younger thanPp .051
5 years with IL-10 responses to EP1 to show significant dif-
ferences; however, no Kisumu children produced IL-10 in re-
sponse to EP1, compared with 11% of Nandi children. The
proportion of IL-10 responders to the EBV latent peptides
(EP2) was too low to show any significant differences within
age groups between the Kisumu and Nandi children. PPD- and
PHA-driven IL-10 responses were significantly less frequent in
1–4-year-olds ( ), and PPD-driven IL-10 responses wereP ! .001
also less frequent in 5–9 year olds from Kisumu than from
Nandi ( ). The proportion of IL-10 responders to PPDP ! .001
and PHA was similar for older Kisumu and Nandi children.
IL-10 responses to the MSP-1 peptides were either absent or
infrequent in children 1–4 years old regardless of study site and
appeared to be similarly infrequent in the older age groups.
The magnitude of IL-10 responses was compared between
age groups (figure 4). The median levels of IL-10 expressed by
the Nandi children in response to the EBV lytic peptides were
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Figure 4. Magnitude of interleukin (IL)–10 enzyme-linked immunospot (ELISPOT) responses, by age group. The magnitude of Epstein-Barr virus (EBV)
lytic (A) and latent (B) IL-10 responses was compared by age group and by residence (Kisumu vs. Nandi) for positive responders only. IL-10 responses
are expressed as picograms per milliliter. The level of IL-10 for each responder is represented as black circles for Kisumu children and as white
squares for Nandi children, and a median bar is shown for each age group.
similar between age groups. There were few or absent IL-10
responses to the EBV lytic and latent peptide pools in the
Kisumu children. The Nandi children had a similar paucity of
IL-10 responses to the EBV latent peptides.
Concordance of EBV-specific IFN-g and IL-10 responses.
The concordance of cytokine responses was examined to de-
termine whether IFN-g nonresponders instead expressed IL-
10. We found that the children were able to express both IFN-
g and IL-10 in response to PHA and PPD but that they tended
to express either IFN-g or IL-10 in response to EBV peptides.
As shown in figure 3, too few children produced IL-10 in re-
sponse to the EBV lytic or latent peptides to reach statistical
significance, yet only 8 of the 88 children with IFN-g responses
to the EBV lytic peptides had concomitant IL-10 responses
regardless of malaria exposure. Similar findings were observed
for responses to the EBV latent peptides. Only 4 of the 71
children with IFN-g responses also produced IL-10.
DISCUSSION
Malaria has been identified as a cofactor in the etiology of eBL
on the basis of the geographic overlap between the prevalence
of this childhood cancer and residency in areas of high malaria
endemicity. Although earlier work using in vitro regression as-
says of EBV outgrowth in peripheral blood suggests that ma-
larial infection suppresses antiviral immunity and thereby fa-
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vors the emergence of neoplastic B cells, the immune basis of
this suppression has not been characterized in detail [22–24].
By comparing IFN-g and IL-10 responses to EBV epitopes in
a cross-section of healthy 1–14-year-old children living in 2
geographically proximate areas of western Kenya in which ma-
laria endemicity ranges from holoendemic (Kisumu) to unsta-
ble and epidemic prone (Nandi), we made several observations
that add to our knowledge of how malaria alters EBV immunity.
First, there was an age-related loss of T cell IFN-g responses
to EBV lytic and latent HLA class I–restricted epitopes in 5–
9-year-old children resident in the malaria-holoendemic area
relative to younger and older children from the same area as
well as children in all age groups from the epidemic-prone area.
Second, the magnitude of IFN-g responses (when a response
was present) was not dependent on age or past malaria ex-
posure. Third, IL-10 responses to EBV lytic peptides, PPD, and
PHA were significantly less frequent in Kisumu children than
in Nandi children, but this difference was resolved in children
19 years old. Considered in the context that the peak age in-
cidence of eBL is 5–9 years [34], these data lend further cre-
dence to the notion that intense malaria exposure during the
first 9 years after birth suppresses CTL IFN-g activity and im-
munosurveillance against EBV-infected B cells at a time when
neoplastic B cells are likely to emerge.
A secondary goal of our study was to determine whether the
diminished childhood IFN-g–mediated immunity to EBV as-
sociated with holoendemic malaria is antigen specific. On the
basis of the observation that the frequency and strength of IFN-
g production in response to MSP-1 peptides, PPD, and PHA
were similar for children in all age groups from both Kisumu
and Nandi, it appears that the age-related loss of immunity is
specific for EBV. These results do not formally exclude the
possibility that reduced T cell IFN-g responses extends to other
microorganisms that commonly infect children in sub-Saharan
Africa. In this regard, ongoing studies aim to determine whether
CD8+ T cell immunity to cytomegalovirus, a persistent her-
pesvirus that is acquired during childhood in rural Africa, is
modified in a manner that is distinct from or similar to that
of EBV.
The cellular and molecular basis of the age-related changes
in EBV immunity reported here, and why in particular T cell
IFN-g responses in 5–9-year-old children are depressed, remain
to be determined. Several mechanisms may be considered. First,
maturation of dendritic cells in 5–9-year-olds may be impaired
as a consequence of chronic malaria exposure, as has been
reported for in vitro studies of dendritic cells exposed to blood-
stage P. falciparum [35]. Second, chronic malaria exposure may
alter antigen processing by dendritic cells and other antigen-
presenting cells through Toll-like receptor antagonism [36–38].
Third, chronic malaria exposure may lead to increased numbers
of regulatory T cells, which decreases IFN-g production by T
cells. A key feature that these potential immune-evasion strat-
egies do not explain is the “recovery” of effector T cell im-
munity in 10–14-year-old children. To our knowledge, no stud-
ies have investigated the maturation of T cell immunity in
children with chronic malarial infection.
We previously quantified EBV loads in 1–14-year-old chil-
dren from Kisumu and Nandi and found that the highest mean
levels were in the youngest age group (1–4 years old) from
Kisumu, where malaria transmission is intense and stable [11].
The EBV-specific IFN-g responses in the youngest age group
could thus be generated by an effector T cell population that
may not adequately contain viral replication and/or latency.
This notion is supported by the lower magnitude of IFN-g
responses to both lytic and latent EBV peptides in the youngest
children. In this context, we determined in the study partici-
pants described here whether high EBV loads were inversely
proportional to EBV-specific IFN-g responses. No correlation
was observed, a finding similar to that reported in studies of
the impact of HIV infection on EBV immunosurveillance [39].
Future work will determine whether this lack of correlation is
related to transient incompetence or immunosuppression of
EBV-specific CD8+ T cells—for example, failure to produce IFN-
g in response to cognate antigen or the presence of immumo-
regulatory T cells that actively suppress cytokine production.
The role played by IL-10 in the pathogenesis of eBL remains,
at this point, speculative. We have previously found an inverse
relationship between cytotoxicity and IL-10 expression in EBV-
specific CD8+ T cell clones [19], and others have reported that
IL-10 potentiates EBV-mediated B cell transformation by in-
hibiting memory T cells [40]. With regard to P. falciparum,
elevated plasma IL-10 levels correlate with greater parasite den-
sities and less-effective parasite clearance in children 1–4 years
old [41]. There are also data suggesting that natural malarial
infections bias toward Th2-like immunity [42, 43]. We there-
fore hypothesized that children with chronic malarial infection
would have prominent EBV-specific IL-10 responses. Thus, the
overall suppression of IL-10 responses in the younger children
from the malaria-holoendemic area was unexpected. This sup-
pression could be indicative of a global pattern of T cell ex-
haustion as a consequence of repeated malaria exposure. The
inverse relationship between EBV-specific IFN-g and IL-10 re-
sponses is consistent with a model for dominant T cell re-
sponses being either Th1 (IFN-g) or Th2 (IL-10). However,
because there were so few IL-10 responders, the significance of
this finding is unclear at this time. A caveat of this interpretation
is that we measured only human IL-10 and not the viral IL-
10 homologue, BCRF1 [44].
Given that the incidence of eBL is ∼2 cases/100,000 children
[3], it is not feasible to evaluate directly immune risk factors
that precede eBL tumorigenesis. Elucidation of how chronic
malaria exposure contributes to the pathogenesis of eBL will
EBV Immunity in Malaria-Exposed Children • JID 2007:195 (15 March) • 807
therefore require comparison with age-matched children pre-
senting with eBL and prospective study of EBV immunity in
healthy children with differing malaria exposure. This approach
will not only advance our understanding of the role played by
T cell immunosurveillance in controlling EBV latency but also
contribute to understanding how malaria-related immunosup-
pression affects the development of immunity to other common
pathogens and childhood vaccines.
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